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Abstract The purpose of this study was to analyze the
evidence supporting a staging model for bipolar disorder.
The authors conducted an extensive Medline and Pubmed
search of the published literature using a variety of search
terms (staging, bipolar disorder, early intervention) to find
relevant articles, which were reviewed in detail. Only
recently specific proposals have been made to apply clin-
ical staging to bipolar disorder. The staging model in
bipolar disorder suggests a progression from prodromal
(at-risk) to more severe and refractory presentations (Stage
IV). A staging model implies a longitudinal appraisal of
different aspects: clinical variables, such as number of
episodes and subsyndromal symptoms, functional and
cognitive impairment, comorbidity, biomarkers, and neuro-
anatomical changes. Staging models are based on the fact
that response to treatment is generally better when it is
introduced early in the course of the illness. It assumes that
earlier stages have better prognosis and require simpler
therapeutic regimens. Staging may assist in bipolar disor-
der treatment planning and prognosis, and emphasize the
importance of early intervention. Further research is
required in this exciting and novel area.
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Introduction
Bipolar disorder is a chronic and recurrent illness, which
represents a major public health problem, and can lead to
incomplete functional recovery, social/family disruptions,
and cognitive impairment, in addition to increased mor-
tality. The World Health Organization’s Global Burden of
Disease Study ranks bipolar disorder as the sixth cause of
years lost to disability (Murray and Lopez 1997).
Although the use of clinical staging is widespread in
medicine, only recently have specific proposals been made
to apply clinical staging to bipolar disorder. The neglect of
staging in mental disorders parallels its reliance on cross-
sectional descriptions rather than the longitudinal study of
prodromes, the fully developed disorder and residual
states (Fava and Kellner 1993). In psychiatry, in addition
to augmenting categorical approaches with symptoms
dimensions (Vieta and Phillips 2007), consideration needs
to be given to issues such as time, severity, persistence, and
recurrence; together with these aspects, biological changes
and the social impact of the disorder could also be drawn
into the definition to produce a clinopathological model
(McGorry et al. 2008). Recently, staging has been sug-
gested by some authors as a course specifier for DSM-V
(McGorry 2007; Colom and Vieta 2009).
As suggested by McGorry (2007), a disorder that is
potentially severe and which may progress if untreated is
likely to be most appropriate for staging; early treatment
should demonstrably increase the chance of cure or at least
of reducing mortality and disability. Therefore, early
treatment may change the prognosis and consequently
prevent progression to subsequent stages.
The natural course of untreated bipolar disorder involves
multiple recurrences, persistent symptoms, potential cogni-
tive impairment, comorbidity, and several neurobiological
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changes. Staging models may help to clarify the mechanisms
underlying the progression of the disorder and assist in
treatment planning and prognosis. The staging model in
bipolar disorder suggests a progression from prodromal to
more severe and refractory presentations, highlighting the
relevance of early intervention. Furthermore, early inter-
vention is usually related to a better response to treatment.
Staging models would allow clinicians to guide prognosis
and therapy according to the different stages of the illness
(Berk et al. 2007a; Kapczinski et al. 2009a).
The aim of this review was to analyze the published
literature about staging models for bipolar disorders and
see to what extent it can help to foster early intervention
strategies.
Methods
The authors conducted an extensive Medline and Pubmed
search of the published English literature using terms that
included bipolar disorder AND (staging OR early inter-
vention). This search returned 142 articles or reviews
between 1982 and 2009. Articles were selected based on
title and abstract and, where necessary, examination of the
full text to assess relevance. Most of them were excluded
because their focus was not staging but other issues related
to bipolar disorder. In addition, reference lists from iden-
tified articles were examined. A search for published arti-
cles written by specific authors who had been working on
staging in other mental disorders was also carried out.
Results
Fifty-seven articles were included in this review. They will
be divided into two main subjects: the basis for a staging
model and the proposed staging models in bipolar disorder.
Grounds for a Staging Model in Bipolar Disorder
The course of bipolar disorder is not uniform, but several
pharmacological (Franchini et al. 1999; Swann et al. 1999;
Ketter et al. 2006) and psychological trials (Scott et al.
2006; Colom et al. in press) have shown that the earlier the
intervention is implemented, the better the response to
treatment. Recent data from a prospective, naturalistic
cohort study showed that the duration of untreated psy-
chosis predicted remission, positive symptoms, and social
functioning at 8 years; continuing functional recovery
between 4 and 8 years was predicted by duration of
untreated illness (Crumlish et al. 2009). Chronicity is
related to significant consequences in the patient’s lives.
Most authors agree that treatment delay in bipolar patients
is linked with poorer social adjustment, higher number of
hospitalizations, increased risk of suicide, development of
comorbidities, forensic complications, and global impair-
ment of the capacity to face developmental tasks in bipolar
patients (Conus et al. 2006). Furthermore, it has been
reported that the duration of euthymia shortens and the risk
of subsequent recurrence increases with each new affective
episode of the illness (Kessing et al. 1998, 2004). Post
(1992) suggested that multiple episodes lead to permanent
alterations in neuronal activity, which may be transduced at
the level of a greater liability to relapse and the potentially
poorer response to medication in patients with multiple
episodes. Therefore, episode frequency and severity,
together with an augmented sensitivity to stress factors,
may increase with the passing of time or with each new
recurrence (Post et al. 1986; Kapczinski et al. 2008a).
It has been reported that early- versus late-stage bipolar
disorder patients differ in terms of biological markers
(Kapczinski et al. 2009a). A staging model for bipolar
disorder should differentiate the neurobiological correlates
of the disorder’s distinct stages (Berk et al. 2007a, b;
Kapczinski et al. 2009a). Some biological factors such as
white matter hyperintensities, with cortical lesions appear
to be associated with a worse prognosis (Moore et al. 2001;
Silverstone et al. 2003). Morphometric studies have dem-
onstrated an enlargement of the third and lateral ventricles
(Soares et al. 2005), reduced gray matter in the hippo-
campus and cerebellum (Moorhead et al. 2007), reduced
volumes in some areas of the prefrontal cortex (Blumberg
et al. 2006; Soares et al. 2005), and an increased size of the
amygdala in patients with bipolar disorder (Blumberg et al.
2006). It has been reported that such neuroanatomical
changes tend to be more pronounced with repeated epi-
sodes and correlate with length of illness (Lyoo et al. 2006;
Strakowski et al. 2002). Therefore, some brain regions,
such as the anterior cingulate and the ventrolateral pre-
frontal cortex, show morphological abnormalities in later
phases of the illness that are likely related to either illness
progression or to the effects of drug treatment (Salvadore
et al. 2008a).
Anatomical changes could be a reflection of changes in
neurotrophic factors and increased pro-apoptotic routes
(Kapczinski et al. 2009b). Among those neurobiological
markers that appear to be involved in the pathophysiology
of bipolar disorder, the brain-derived neurotrophic factor
(BDNF) has received special attention due to its role in
regulating neuronal survival, structure, and function.
BDNF (Cunha et al. 2006), as well as other neurotrophins
such as NT3 (Walz et al. 2007), NT4 (Walz et al. 2009),
and GDNF (Rosa et al. 2006) appear to be altered in
bipolar disorder mood episodes. Furthermore, recent
findings have showed that biochemical markers may
change significantly from the early to late stages of
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bipolar disorder (Kauer-Sant’Anna et al. 2009; Andreazza
et al. 2009). The TNF-alpha and IL-6 cytokines were
shown to be increased in early and late stage of bipolar
disorder compared to controls, whereas BDNF levels were
decreased in the late but not early stage of bipolar dis-
order (Kauer-Sant’Anna et al. 2009). The levels of the
anti-inflammatory cytokine IL-10 also declined in the
late-stage disorder (Kauer-Sant’Anna et al. 2009). These
and other findings (Cunha et al. 2008) indicate that
patients with bipolar disorder are likely to be in a pro-
inflammatory state (Brietzke and Kapczinski 2008; Bri-
etzke et al. 2009), which worsens in the later stages of the
illness. Some parameters of oxidative stress, such as
3-nitrotyrosine, are also altered in the early stages of
bipolar disorder; while others, such as glutathione trans-
ferase (GST) and glutathione reductase (GR), differ from
controls only in those patients with multiple episodes in
later stages of bipolar disorder (Andreazza et al. 2009).
Data also suggest that the lowering of BDNF levels in
acute episodes occurs in parallel with increased oxidative
stress, suggesting that such changes occur in an orches-
trated fashion (Kapczinski et al. 2008b). Oxidative stress
plays a key role in the induction of DNA damage, endothelial
dysfunction, and telomere shortening (Kapczinski et al.
2008a). Bipolar patients presented an increase of frequency
of DNA damage when compared to controls. The frequency
of DNA damage correlates with the severity of symptoms of
depression and mania (Andreazza et al. 2007). An acceler-
ated aging process has been also suggested in bipolar dis-
order, as indicated by increased telomere shortening (Simon
et al. 2006) and greater age-related decreases in BDNF levels
in bipolar patients compared to controls (Yatham et al.
2009).
Taken together, these findings suggest that with multiple
mood episodes and longer duration of illness, the neuro-
protective mechanisms become less effective and the del-
eterious effects of these biological changes become more
apparent. This is in accordance with the staging model of
bipolar disorder and provides some support for the theory
of involvement of allostatic process in bipolar patients. The
term ‘‘allostatic load’’ refers to a cumulative, multisystem
view of the physiological toll that is required for adaptation
to stress. Oxidative stress, neurotrophic factors, and the
immune-inflammatory system genes were identified as
mediators of allostatic load. The effects of allostatic load
are cumulative and most notably seen during the process of
aging and acute and chronic stress. The allostatic load
concept supports the theory that early intervention may
promote better treatment response and clinical outcome for
bipolar patients.
To sum up, early therapeutic interventions may play a
neuroprotective role reducing neurobiological abnormalities
linked to the illness (Vieta et al. in press). The timing of
neurobiological changes suggests that the optimal period
for neuroprotective interventions is either the prodromal
phase or during the early stages of the illness (Salvadore
et al. 2008b). There is increasing evidence that agents such
as lithium and valproate have significant neuroprotective
properties (Frey et al. 2006).
In addition, cognitive deficits seem to be related to the
severity of the disease (Martı´nez-Ara´n et al. 2007), being
more evident in patients who have experienced multiple
episodes (Torres et al. 2007). Greater neuropsychological
dysfunction in bipolar disorder has been associated with a
worse prior course of the illness, particularly the number of
manic episodes, hospitalizations, and length of illness
(Robinson and Ferrier 2006), although there is a lack of
prospective, longitudinal studies on this area. Deficits in
memory, attention, and planning have been consistently
reported in euthymic bipolar patients. Such deficits appear
to be related to impairment in distinct domains of func-
tioning (Martı´nez-Ara´n et al. 2007); memory deficits may
represent a serious problem for bipolar patients with con-
sequent effect on their work productivity as well as more
difficulties in their interpersonal relationships. Significant
functional impairment has been found in bipolar patients
even in remission (Rosa et al. 2009). Neurocognitive
symptoms can have a clinical value as they can lead to the
acquisition of more information about the brain areas and
functions involved in the pathogenesis of the disease, and
they might also be useful as potential endophenotypes.
Cognitive deficits are predictive of worse functional out-
come at 4-year follow-up (Bonnı´n et al. in press). Both
cognitive and functional impairment represent a potential
target for prophylactic treatment, their assessment should
be considered in clinical practice.
Other aspects that have also been related to a poor
outcome are subsyndromal symptoms and psychiatric
comorbidity. Particularly, subsyndromal depressive symp-
toms have been consistently associated with poor cognitive
and occupational functioning (Rosa et al. 2009). Regarding
comorbidity, those most frequently observed in bipolar
disorder are substance-use disorders and anxiety disorders
(McElroy et al. 2001). It is unclear whether disorders
usually classified as comorbidities are truly biologically
separate conditions, biologically antecedent risk markers,
prodromal illness expressions, artifacts of overlapping and
imperfect classification systems, or bipolar disorder sub-
types (Correll et al. 2007). However, comorbidity and its
negative impact could be reduced by an early diagnosis and
appropriate treatment; which is not always the case in
bipolar disorders.
All the factors mentioned have been considered by
staging models for bipolar disorders.
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Proposed Staging Models in Bipolar Disorder
Clinical assessment added to the evaluation of psychoso-
cial and cognitive functioning and peripheral biomarkers in
the interepisodic period may offer a consistent set of data
that, analyzed in the light of genomic and neuroimaging
findings, may help to create a model of staging. Clinical
staging in psychiatry was first proposed by Fava and
Kellner (1993) and developed by the McGorry group
(2006) for psychotic and severe mood disorders. Different
staging models have been proposed in bipolar disorder
(Berk et al. 2007b; Kapczinski et al. 2009a), although they
need to be better operationalized and validated by empir-
ical research. Berk et al. (2007b) have reported that stage of
illness is a clinical descriptor that has utility in conceptu-
alizing bipolar disorders, and for devising an individualized
needs-based model. Therefore, a staging model in bipolar
disorder may be constructed in parallel to therapeutic
algorithms, linking stage to specific treatment needs and
possible therapeutic options.
Staging highlights the importance of the identification of
at-risk individuals due to early diagnosis and prompt ini-
tiation of therapy is crucial to improve outcome. Berk et al.
(2007b) have suggested a model adapted from McGorry
et al. (2006). The disorder begins with an at-risk, asymp-
tomatic period, where a range of risk factors (e.g., family
history, substance use) may be operating (Stage 0). Indi-
viduals begin to exhibit mild or non-specific symptoms of
mood disorder (Stage 1a), and may progress to manifest the
range of prodromal patterns (Stage 1b). These may cul-
minate in a first threshold episode of illness (Stage 2),
which can be of either polarity, but is more commonly
depressive. This may be followed by a first relapse, either
subthreshold (Stage 3a), or threshold illness (Stage 3b),
followed by a subsequent pattern of remission and recur-
rences (Stage 3c). While some individuals may recover
syndromally or symptomatically, others may have an
unremitting or treatment-refractory course (Stage 4).
Course and expression of illness variables, the diagnostic,
and pharmacological and psychotherapeutic issues relevant
to each illness stage differ substantially. There is a further
impact of comorbidity, specific treatment, personality,
adherence, and response to therapy. In contrast to the early
phases in which the focus would be on early intervention
and neuroprotective strategies, in the later stages the
emphasis would be more rehabilitative treatments dealing
with the disabilities of the illness. As has been suggested by
Berk et al. (2009), early intervention is the critical ingre-
dient if the promise of neuroprotection is to be actualized.
Early initiation of optimal therapy similarly allows the
secondary prevention of the sequelae of untreated illness
including impacts on family relationships, psychosexual
and vocational development, identity, and a concept of self.
The initial proposal of bipolar disorder staging put for-
ward by Berk et al. (2007a, b) was further developed by
Kapczinski et al. (2009a, b). Such a model implies a lon-
gitudinal appraisal of clinical variables as well as assess-
ment of comorbidity, functioning, neurocognition, and
biomarkers in the inter-episodic period. It suggests a pro-
gression from a latent (at-risk) period to more severe and
refractory presentations engendered by cumulative expo-
sure to acute episodes, substance abuse, life stress, and
inherited vulnerability. This model emphasizes the
assessment of patients in the inter-episodic period and
includes a latent phase and four stages. Latent phase:
individuals who present mood and anxiety symptoms and
increased risk (e.g., positive family history) for developing
threshold bipolar disorder, they do not show cognitive
impairment but polymorphisms that confer susceptibility to
the illness. Stage I: patients with bipolar disorder who
present well-established periods of euthymia and absence
of overt psychiatric morbidity between episodes, without
cognitive impairment but high levels of TNF and
3-Nytrotyrosine as biomarkers. Stage II: patients who
present rapid cycling or current axis I or II comorbidities,
transient impairment and, as biomarkers, they show high
levels of TNF and 3-Nytrotyrosine and lower BDNF levels.
Stage III: patients who present a clinically relevant pattern
of cognitive and functioning deterioration (unable to work
or very impaired performance) as well as altered bio-
markers (morphometric changes in brain may be persistent,
high levels of TNF and 3-Nytrotyrosine and lower BDNF
levels). Stage IV: patients, who show cognitive and func-
tional impairment, are unable to live autonomously and
present altered brain-scans and biomarkers (ventricular
enlargement and/or white matter hyperintensities, high
levels of TNF and 3-Nytrotyrosine and lower BDNF levels,
increased levels of Glutathione reductase and transferase).
The authors have also made some therapeutic and prog-
nostic suggestions linked to the illness stage. Whereas in
early stages mood stabilizer monotherapy or a combined
treatment (pharmacological monotherapy plus psychologi-
cal treatment) would be enough, complex regimens or
palliative measures would be required in advanced stages.
Staging facilitates understanding the mechanisms under-
lying progression of the disorder, assists in treatment
planning and prognosis, and finally, underscores the
imperative for early intervention. This understanding
additionally identifies the first illness episode as a critical
target for early intervention, creating the hope of being able
to prevent some of the neuroanatomical, neuropsycholog-
ical, clinical and functional consequences of the illness
(Kapczinski et al. 2009b).
Based on the criteria proposed by Kapczinski et al.
(2009a) and focused on clinical and functioning factors,
Reinares et al. (2010) carried out a post-hoc analysis of a
282 Neurotox Res (2011) 19:279–285
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controlled-randomized study on psychoeducation delivered
to caregivers of bipolar patients. For the purpose of this
study, the bipolar sample was divided into two groups
(Stage I, and Stages II, III, and IV taken together). Psy-
choeducation for caregivers of bipolar patients on Stage I
showed improvement in long-term outcome regarding time
to recurrence, highlighting the importance of early inter-
vention as some treatments can be especially useful in
patients with lower severity. Future studies should con-
tribute to the validation of the staging models as a way to
help to guide treatment selection and prognosis.
A recent study concluded that clinical staging might be a
useful approach to refine the early diagnosis and facilitate
research into the evolution of bipolar disorder in subjects at
familial risk (Duffy et al. 2010). Since some patients with
bipolar disorder lack a first-degree relative with the illness,
it has been suggested that early detection of individuals at
risk for bipolar disorder should combine genetic, endo-
phenotypic, and clinical methods (Correll et al. 2007). The
great majority of individuals experienced a symptomatic
prodromal phase prior to the first episode; however, for the
identification of individuals in subsyndromal or attenuated
symptoms, it is still an under-researched area that could be
improved by the development of rating tools that could be
introduced systematically in primary care, paying special
attention to young people. A better understanding of the
factors that influence progression from one stage to the
next is also needed, as they may respond to therapeutic
interventions.
Conclusions
The analysis of the current scientific literature supports the
statement that a clinical staging model may help to validate
or redefine clinical boundaries, distinguish true patho-
physiology from epiphenomena or sequelae, and enable
much existing data to be better understood (McGorry
2007). Although different staging models have been pro-
posed in bipolar disorder, they need to be better opera-
tionalized and validated by empirical research. So far, most
of the available evidence supporting the potential use of
staging in the field of bipolar illness comes from the clin-
ical arena and seems consistent with neurocognitive, bio-
chemical, as well as neuroimaging findings. However,
there is only evidence for differences between patients at
relatively early stages versus late stages (characterized by
chronicity and high-allostatic load), but not for a greater
number of stages with specific therapeutic implications.
Hence, it seems too early to include staging as a potential
course specifier in the forecoming new editions of diag-
nostic systems, but its use may help to raise awareness on
the need to shorten the time since illness onset on one hand,
and diagnosis and effective treatment, on the other. Early
intervention in bipolar disorders depends on the ability to
identify individuals at high risk for developing the illness.
A model of staging might not only help to predict response
to treatment but also general outcome measures, such as
the level of functioning and autonomy. In the near future,
several models of staging should be tested and validated in
the context of epidemiological studies, underlying neuro-
biology, and clinical trials. The staging model may become
a useful way to bridge the gap between traditional evi-
dence-based medicine and personalized medicine in the
area of bipolar disorder.
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